Cadila Healthcare has got approval from United States Food & Drug Administration (USFDA) to market droxidopa capsules. The drug will be manufactured at the Group's formulation manufacturing facility at the SEZ, Ahmedabad. Droxidopa capsules are used for treating low blood pressure.
It works by constricting the blood vessels and increasing blood pressure. Low blood pressure can cause severe dizziness or a light-headed feeling. It is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).
The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04, according to a report by Business Standard. The announcement was made during market hours.
Cadila Healthcare reported 40.6 per cent rise in consolidated net profit to Rs 512.50 crore on a 6.2 per cent rise in net sales to Rs 3,753.70 crore in Q3 FY21 over Q3 FY20. Shares of Cadila Healthcare lost 1.67 per cent to Rs 459.70 on BSE. Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Phillips Carbon Flags Off Two Specialty Black Lines in Palej
Inox Wind Receives New Orders for 62 MW Wind Turbine Generators